238 related articles for article (PubMed ID: 22782520)
21. Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.
Guo S; Pelligra C; Saint-Laurent Thibault C; Hernandez L; Kansal A
Pharmacoeconomics; 2014 Jun; 32(6):559-72. PubMed ID: 24643323
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.
Kendrick M; Johnson KI
Pharmacoeconomics; 2000 Jul; 18(1):45-53. PubMed ID: 11010603
[TBL] [Abstract][Full Text] [Related]
23. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
24. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
[TBL] [Abstract][Full Text] [Related]
25. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
[TBL] [Abstract][Full Text] [Related]
26. Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Montgomery S; Kusel J; Allen F; Adlard N
Appl Health Econ Health Policy; 2016 Oct; 14(5):545-58. PubMed ID: 27130689
[TBL] [Abstract][Full Text] [Related]
27. Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.
Thompson JP; Abdolahi A; Noyes K
Pharmacoeconomics; 2013 Jun; 31(6):455-69. PubMed ID: 23640103
[TBL] [Abstract][Full Text] [Related]
28. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management.
Owens GM
Am J Manag Care; 2016 Jun; 22(6 Suppl):s151-8. PubMed ID: 27356024
[TBL] [Abstract][Full Text] [Related]
29. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity.
Grudzinski AN; Hakim Z; Cox ER; Bootman JL
Pharmacoeconomics; 1999 Mar; 15(3):229-40. PubMed ID: 10537431
[TBL] [Abstract][Full Text] [Related]
30. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
[TBL] [Abstract][Full Text] [Related]
31. Brain health: time matters in multiple sclerosis.
Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
[TBL] [Abstract][Full Text] [Related]
32. [Multiple sclerosis: cost of the illness].
Tissot E; Woronoff-Lemsi MC
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1169-74. PubMed ID: 11787352
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
[TBL] [Abstract][Full Text] [Related]
34. The cost of multiple sclerosis in Australia.
Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
[TBL] [Abstract][Full Text] [Related]
35. Reducing costs while enhancing quality of care in MS.
Kister I; Corboy JR
Neurology; 2016 Oct; 87(15):1617-1622. PubMed ID: 27590294
[TBL] [Abstract][Full Text] [Related]
36. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada.
Gerber B; Cowling T; Chen G; Yeung M; Duquette P; Haddad P
Mult Scler Relat Disord; 2017 Nov; 18():218-224. PubMed ID: 29141814
[TBL] [Abstract][Full Text] [Related]
37. Impact on healthcare resource utilization of multiple sclerosis in Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
[TBL] [Abstract][Full Text] [Related]
38. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
39. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
40. Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O; Calleja-Hernández MA; Meca-Lallana J; Oreja-Guevara C; Polanco A; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):321-333. PubMed ID: 28726515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
